Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Preoperative Chemoradiotherapy With Capecitabine With or Without Temozolomide in Patients With Locally Advanced Rectal Cancer; A Prospective Randomised Phase 2 Study Stratified by MGMT (O6-methylguanine DNA Methyltransferase) Status

Next Previous
X
Search
Trial Profile

Preoperative Chemoradiotherapy With Capecitabine With or Without Temozolomide in Patients With Locally Advanced Rectal Cancer; A Prospective Randomised Phase 2 Study Stratified by MGMT (O6-methylguanine DNA Methyltransferase) Status

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Temozolomide
  • Indications Adenocarcinoma; Rectal cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 06 Sep 2023 Status changed from recruiting to completed.
    • 07 Jun 2022 Results (n=60) evaluateing the clinical efficacy of adding temozolomide to preoperative capecitabine based chemoradiotherapy in patients with locally advanced rectal cancer and validating O6 methylguanine DNA methyltransferase methylation status as a predictive marker for TMZ combined regimens, presented at the 58th Annual Meeting of the American Society of Clinical Oncology
    • 17 Jan 2021 Planned End Date changed from 1 Feb 2021 to 1 Feb 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top